Navigation Links
London Genetics and Astrimmune to Collaborate on Cancer Vaccine
Date:11/12/2010

London Genetics and Astrimmune to Collaborate on Cancer Vaccine -- LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Joint Ventures, New Products & Services Click to view news release full screen  

London Genetics and Astrimmune to Collaborate on Cancer Vaccine

 

LONDON and NOTTINGHAM, England, November 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme. The plan, for Astrimmune's early-stage pancreatic cancer vaccine candidate, will be used in applications for further funding of its development. Financial terms were not disclosed.

Astrimmune's vaccine candidate induces the production of antibodies against gastrin, a hormone which is known to stimulate the growth of many types of gastrointestinal cancer. Since differential response rates have been observed in clinical trials of other gastrin-blocking products, with some patients responding very well and others hardly at all, there is a clear need for biomarkers to help identify those patients most likely to benefit from Astrimmune's product. For example, there is a possibility that the variable response rates may have been due in part to the inclusion of some patients with gastrin-insensitive tumours, or those not able to respond immunologically.

Under the terms of the collaboration, which is supported by a grant from the UK East Midlands Development Agency, London Genetics and Astrimmune will put together a proposal for identification of biomarkers predictive of clinical response. London Genetics' seven academic partners, which have an annual research budget of over GBP650m, are able to provide expertise in areas such as tumour biopsy samples and animal models, as well as expertise in the genetics of immune responses to cancer vaccines.

Dominique Kleyn, CEO of London Genetics, said, 'This collaboration is a significant pharmacogenetics development opportunity, and we are pleased to be working with Astrimmune on this important project. As exemplified by our recent collaboration with Diaceutics and increasingly recognised by the biopharmaceutical industry, pharmacogenetics, biomarkers and patient stratification are becoming an important part of the drug discovery and development process. London Genetics' network of over 3,000 academic groups makes it an ideal partner for pharma and biotech companies in this work.'

Fred Jacobs, Managing Director of Astrimmune, said, 'Pancreatic cancer is an area of serious unmet medical need, with a five-year survival rate of around 5% and few treatment options. Availability of a biomarker to select those patients mostly likely to benefit from Astrimmune's vaccine candidate can be expected to expedite the development of this product and increase its chances of coming to market in the future. London Genetics is an expert in this area and Astrimmune is delighted to be working with the company on this important part of the project development.'

About London Genetics: London Genetics Limited, a not-for-profit company, is an expert in the use of pharmacogenetics in clinical drug discovery and development. Established in 2007 with funding from the London Development Agency, its seven founding partners are leading London academic and medical institutions with clinical and genetic expertise and significant patient resources. The company provides pharmaceutical and biotechnology companies with access to this expertise and resource, as well as providing strategic advice on the application of pharmacogenetics for successful drug development. LGL has broad therapeutic expertise, based on its access to 3,000 academic groups with a GBP650m annual research spend. Recent deals by London Genetics include a partnership with Diaceutics to accelerate biomarker development in the biopharmaceutical industry. LGL is based in central London and has ISO 9001 accreditation. For further information, please go to http://www.londongenetics.com

About Astrimmune: Astrimmune (Company Registration: 06379008), is a limited, social enterprise company developing treatments for gastrointestinal cancers. Astrimmune is focussed on the elimination of cancer growth factors that are not yet commercialised and is progressing a new immunogen vaccine candidate for use in gastro-intestinal cancers. The distillation of their prior knowledge, coupled with a research programme to refine patient selection to identify the most responsive patients, provides for an accelerated, low cost development path with an increased chance of successful product registration in the EU and the US. For further information, please go to http://astrimmune.blogspot.com/

For further information please contact: London Genetics Ltd Dominique Kleyn, CEO +44(0)207-594-1838 Emma Palmer Foster, Strategic Communications Consultant +44(0)7880-787185 communications@londongenetics.com Astrimmune Fred Jacobs, Managing Director +44(0)7989-386326
'/>"/>

SOURCE London Genetics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
2. OXIS International, Inc. Announces Its Attendance at the Rodman & Renshaw Annual Global Investment Conference in London, May 16-18, 2010
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. First Awards Made by London Genetics Proof-of-Concept Fund
5. Expanded London Genetics Web Site Emphasises Importance of Pharmacogenetics in Drug Development
6. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
7. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
8. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
9. Interleukin Genetics Reports Third Quarter 2010 Financial Results
10. Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease
11. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, 2016 ... Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, the ... announced today online at www.diabetesscholars.org by the ... diabetes stand in the way of academic and community ... Foundation,s scholarship program since 2012, and continues to advocate ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
Breaking Medicine News(10 mins):